Wednesday, 08 Apr 2020

You are here

No Cancer Risk with Systemic Necrotizing Vasculitis

The French Vasculitis Study Group has published that patients with systemic necrotizing vasculitis do not have an increased risk of malignancy; in fact they have a risk that is similar to the general population.

Previous reports have suggested either no risk or a declining risk in the era of better therapies for vasculitis. 

The studied 733 SNV patients for a total of 4485.9 person-years (PY) from five randomised controlled trials (CHUSPAN, CHUSPAN 2, WEGENT, CORTAGE and MAINRITSAN) in SNV conducted by the French Vasculitis Study Group.  The primary endpoint was the occurrence of malignancy. 

All told, there were 39 (5.3%) patients with malignancies (869.5 per 100 000 PY), including solid cancers in 34 (4.6%) cases (757.9 per 100000 PY) and hematological malignancies in 5 (0.7%) cases (111.5 per 100000 PY).  The median interval from inclusion to malignancy’s diagnosis was 4.1 years.

The standardized incidence ratios (SIR) for all cancers showed no difference between this cohort and the general population described in the French National registry3 (SIR 0.95 (0.68–1.30); p=0.84).

Risk of malignancy’s occurrence was more likely with:

  • Age ≥65 years (HR 2.38 (1.13 to 4.99); p=0.022)
  • Azathioprine (HR 3.05 (1.10 to .42); p=0.032) or
  • Methotrexate (HR 3.24 (1.07 to 9.81); p=0.038) as maintenance after cyclophosphamided induction

The use of cyclophosphamide induction with rituximab as maintenance therapy was not associated with malignancy (HR 2.65 (0.48 to 14.64); p=0.262). 

Malignancy was associated with a poorer survival (median 12.1 years). The cause of death was directly related to the malignancy or its treatment in all 19 (100%) patients with cancer who died.

Whereas the use of conventional immunosuppressive regimens was associated with a higher risk of malignancy, the use of rituximab was not associated with a subsequent malignancy risk.  These findings suggest that malignancy should no longer be considered as a predominant feature driving the therapeutic strategy.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Rheumatic Disease Drugs and COVID-19

We are in the early stages of trying to limit the morbid and mortal consequences of the corona virus pandemic of 2020. Not surprisingly, the recommendations designed to limit exposure and damage continually highlight the fact that the elderly and immunosuppressed may be amongst the most severely affected should they become infected with this virus. This has led to a great deal of uncertainty by patients and providers about how rheumatic diseases and their treatments need to be specifically addressed.

EMA Final Recommendations on VTE Risk with Tofacitinib

On 14 November 2019 the European Medicines Agency (EMA) concluded that Xeljanz (tofacitinib) could increase the risk of blood clots in the lungs and in deep veins in patients who are already at high risk.  These recommendations have been formally published and are intended for EU nations utilizing tofacitinib.

Drug Interactions with Cannabinoids

Cannbinoids are widely available and used for a variety of indications, but little is known about their safety and their potential for drug interactions. The Canadian Medical Journal has published a review of drug interactions with cannabinoids, many of which are mediated by cytochrome-P450 metabolism.

Overmedication of America

Recent research from the Lown Institute reports that 750 older Americans are hospitalized daily because of serious side effects from and the core problem is that of polypharmacy, especially in the elderly. 

Best of 2019 - Biologic Safety Guidelines from the British Society for Rheumatology

In the United Kingdom, NICE has looked to the British Society of Rheumatology (BSR) to develop evidence based guidance on the safe use of biologic DMARDs in patients with inflammatory arthritis. This guidance document on biologic safety covers baseline screening, monitoring, effect of co-morbidities, and when or under what circumstances biologic therapy should be interrupted.